Please login to the form below

Not currently logged in
Email:
Password:

ChemoCentryx

This page shows the latest ChemoCentryx news and features for those working in and with pharma, biotech and healthcare.

GSK hands back rights to ChemoCentryx drug

GSK hands back rights to ChemoCentryx drug

GSK hands back rights to ChemoCentryx drug. Investigational IBD treatment vercirnon disappoints in phase III. ... GSK dropped another drug from the initial collaboration earlier this year, but is still working with ChemoCentryx on drugs targeting

Latest news

  • Takeda files IBD drug vedolizumab in Europe Takeda files IBD drug vedolizumab in Europe

    Growth for vedolizumab and other new entrants such as Johnson &Johnson's interleukin-23 inhibitor Stelara (ustekinumab) and GlaxoSmithKline/ChemoCentryx' vercirnon in Crohn's - and Pfizer's JAK inhibitor tofacitinib in

  • GSK licenses arthritis drug from ChemoCentryx

    GlaxoSmithKline (GSK) has licensed a second compound developed under its collaboration with ChemoCentryx. ... If it is approved, ChemoCentryx stands to receive double-digit royalties on sales.

  • GSK to tackle inflammatory bowel disease

    GSK to tackle inflammatory bowel disease. GSK has exercised an option to further develop ChemoCentryx's Traficet-EN (CCX282-B) for the treatment of inflammatory bowel disease. ... Under the terms of the collaboration, ChemoCentryx will receive an option

  • Pharma news in brief

    syndrome. ChemoCentryx will receive an upfront payment of $63.5m in both cash and an equity investment. ... The collaboration covers several projects, including ChemoCentryx's drug, Traficet-EN, which is already in late-stage development for inflammatory

  • A bright start

    The group has formed a strategic alliance with US-based ChemoCentryx to develop and market treatments for various inflammatory disorders in a licensing deal that could be worth up to ... ChemoCentryx is to receive an upfront $63.5m payment comprising

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the complement 5a receptor (C5aR) for ... In return for the expanded territory, Vifor is paying

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics